




[Handwritten signature]

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/809,831	
	Filing Date	March 26, 2004	
	First Named Inventor	Thomas R. KOZEL et al.	
	Group Art Unit	1646	
	Confirmation No.	7955	
Total Number of Pages in This Submission		Attorney Docket Number	031673-3000

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Preliminary Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input type="checkbox"/> Request for Corrected Filing Receipt with Enclosures <input type="checkbox"/> A self-addressed prepaid postcard for acknowledging receipt <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO-1449 Form (4 Sheets) 23 References
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Jeffrey A. Lindeman – Reg. No. 34,658 Nixon Peabody LLP 401 9 th Street, N.W. Suite 900 Washington, D.C. 20004-2128
Signature	<i>[Handwritten Signature]</i>
Date	July 18, 2005

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop _____, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) _____.	
_____ Date	_____ Signature
	_____ Typed or printed name



Application No. 10/809,831
Docket No. 031673-3000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	
Thomas R. KOZEL et al.)	
Application No. 10/809,831)	Group Art Unit: 1646
Filed: March 26, 2004)	Confirmation No. 7955
For: COMPOSITIONS AND METHODS FOR)	Examiner: Not Yet Assigned
DETECTION, PREVENTION, AND)	
TREATMENT OF ANTHRAX AND)	July 18, 2005 <i>JAL</i>
INFECTIOUS DISEASES)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing of this application or entry into the national stage of this application, or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initial a copy of this form be returned to the undersigned.



The Commissioner is hereby authorized to charge any fees connected with this filing which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,

By: _____

Jeffrey A. Lindeman
Jeffrey A. Lindeman
Registration No. 34,658

NIXON PEABODY LLP
Suite 900
401 9th Street, N.W.
Washington, DC 20004-2128
Telephone: (202) 585-8000



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	10/809,831
Filing Date	March 26, 2004
First Named Inventor	Thomas R. KOZEL et al.
Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	031673-3000

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Schneerson, R. et al., "Poly(γ -D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of <i>Bacillus anthracis</i> : A potential addition to the anthrax vaccine", Proc. Natl. Acad. Sci. U.S.A., 7/2003, Vol. 100 (15), pgs. 8945-8950.	
		Rhie, G. E., et al. "A dually active anthrax vaccine that confers protection against both bacilli and toxins", Proc. Natl. Acad. Sci. U.S.A., 9/2003, Vol. 100 (19), pg. 10925-10930.	
		Dixon, T. C., et al., "Anthrax", N. Engl. J. Med., 1999, Vol. 341, pgs. 815-826.	
		Ross, J. M., "The Pathogenesis of Anthrax Following the Administration of Spores by the Respiratory Route", J. Path. Bact., 1957, Vol. 73, 485-494.	
		Guidi-Rontani, C., et al., "Germination of <i>Bacillus anthracis</i> spores within alveolar macrophages", Molecular Microbiology, 1999, Vol. 31, pgs. 9-17.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>		
				Application Number		10/809,831
				Filing Date		March 26, 2004
				First Named Inventor		Thomas R. KOZEL et al.
				Group Art Unit		1646
				Examiner Name		Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number		031673-3000

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Dixon, T. C., et al., "Early <i>Bacillus anthracis</i> -macrophage interactions: intracellular survival and escape", Cellular Microbiology, 2000, Vol. 2(6), pgs. 453-463.	
		Kochler, T. M., et al., "Regulation of the <i>Bacillus anthracis</i> Protective Antigen Gene: CO ₂ and a <i>trans</i> -Acting Element Activate Transcription from One of Two Promoters", Journal of. Bacteriology, 2/1994, Vol. 176, No. 3, pgs. 586-595.	
		Inglesby, T. V., et al., "Anthrax as a Biological Weapon, 2002, JAMA, 5/2002, Vol. 287, No. 17, pgs. 2236-2252.	
		Kalns, J., et al. "Delayed treatment with doxycycline has limited effect on anthrax infection in BLK57/B6 mice", Biochemical. and Biophysical Research Communications., 2002, Vol. 297, pgs. 506-509.	
		Dullforce, P., et al., "Enhancement of T cell-independent immune responses <i>in vivo</i> by CD40 antibodies", Nature Medicine., January 1998, Vol. 4, pgs. 88-91.	
		Leonard, C. G., et al., "Effects of Some Metallic Ions on Glutamyl Polypeptide Synthesis by <i>Bacillus Subtilis</i> ", J. Bacteriol., 5/1958, Vol. 76, pgs. 499-503.	
		Dubois, M., et al., "Colorimetric Method for Determination of Sugars and Related Substances", Anal. Chem., 3/1956, Vol. 28, pgs. 350-356.	
		Hixon, J. A., et al., "Antibodies to CD40 Induce a Lethal Cytokine Cascade After Syngeneic Bone Marrow Transplantation", Biology of Blood Marrow Transplantation, 2001, Vol. 7, pgs. 136-143.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>			
				Application Number		10/809,831	
				Filing Date		March 26, 2004	
				First Named Inventor		Thomas R. KOZEL et al.	
				Group Art Unit		1646	
				Examiner Name		Not Yet Assigned	
Sheet	3	of	4	Attorney Docket Number		031673-3000	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Leinonen, M., et al., "Class-Specific Antibody Response to Group B <i>Neisseria meningitidis</i> Capsular Polysaccharide: Use of Polylysine Precoating in an Enzyme-Linked Immunosorbent Assay", <i>Infection and Immunity</i> , 12/1982, Vol. 38, No. 3, pgs. 1203-1207.	
		Brandt, S., et al., "Monoclonal Antibodies Reactive with Immunorecessive Epitopes of Glucuronoxylomannan, the Major Capsular Polysaccharide of <i>Cryptococcus neoformans</i> ", <i>Clinical Diagnostic Laboratory Immunology</i> , 9/2003, Vol. 10, No. 5, pgs. 903-909.	
		Ouchterlony, Ö., "In vitro Method for Testing the Toxin-Producing Capacity of Diphtheria Bacteria", <i>Acta Pathol. Microbiol. Scand.</i> , 1948, Vol. 25, pgs. 186-191.	
		Uchida, I., et al., "Identification of a novel gene, <i>dep</i> , associated with depolymerization of the capsular polymer in <i>Bacillus anthracis</i> ", <i>Molecular Microbiology</i> , 1993, Vol. 9(3), pgs. 487-496.	
		Jernigan, J., et al., "Bioterrorism-Related inhalational Anthrax: The First 10 Cases Reported in the United States", <i>Emerging Infectious Diseases.</i> , Nov./Dec. 2001, Vol. 7, pgs. 933-944.	
		Borio, L., et al., "Death Due to Bioterrorism-Related Inhalational Anthrax", <i>JAMA</i> , 11/2001, Vol. 286, No. 20, pgs. 2554-2559.	
		Casadevall, A., "Antibodies for defense against biological attack", <i>Nature Biotechnology</i> , 2/2002, Vol. 20, pg. 114.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/809,831
				Filing Date	March 26, 2004
				First Named Inventor	Thomas R. KOZEL et al.
				Group Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	031673-3000

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Goodman, J. W., et al., "Immunochemical Studies on the Poly-γ-D-glutamyl Capsule of <i>Bacillus anthracis</i> . I. Characterization of the Polypeptide and of the Specificity of Its Reaction with Rabbit Antisera", BIOCHEMISTRY., 2/1966, Vol. 5, pgs. 657-665.	
		Zink, G. L., "Immunizing Agents and Diagnostic Antigens", Remington's Pharmaceutical Sciences, 1980, Mack Publishing Co., Easton, Pa., pgs. 1324-1341.	
		Nieto, <i>et al.</i> , "Direct Measurement of Antibody Affinity Distribution by Hapten-Inhibition Enzyme Immunoassay", Molecular Immunology, 1984, Vol. 21, pgs. 537-543.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.